Physician profile
Alan Kaye
NPI 1558308643
$3,455.98
in general payments reported to CMS, 2019-2025
36 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,510 · 2020: $348 · 2021: $11.60 · 2022: $26.00 · 2024: $504 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,560.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $312.36 | 2019-2025 | Airsupra |
| Pfizer INC. | $296.42 | 2019-2025 | |
| Amgen INC. | $256.88 | 2019-2025 | Evenity, Otezla, Repatha |
| Abbott Laboratories | $256.74 | 2024-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $247.74 | 2019-2020 | |
| Novo Nordisk INC | $245.13 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $197.67 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $151.30 | 2019-2025 | Veozah |
| Inspire Medical Systems, INC. | $145.29 | 2024 | Inspire |
| Sanofi-Aventis U.S. LLC | $134.77 | 2019-2025 | |
| Abbvie INC. | $124.07 | 2025 | |
| Amarin Pharma, INC. | $118.11 | 2019-2020 | |
| Lilly USA, LLC | $117.80 | 2020-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $91.31 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Arbor Pharmaceuticals, INC. | $81.61 | 2019-2020 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kaye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.